PharmaShots | Incisive News in 3 Shots

Subscribe Now

regeneron

Regeneron and Sanofi Report the US FDA Acceptance of sBLA for Priority Review of Dupixent to Treat Eosinophilic Esophagitis in Children Aged 1-11Years

Regeneron and Sanofi Report the US FDA Acceptance of sBLA for Priority Review of Dupixent to Treat Eosinophilic Esophagitis in Chi...

September 26, 2023

Regeneron’s Eylea HD (aflibercept) Receives the US FDA’s Approval for Serious Retinal Disease

Regeneron’s Eylea HD (aflibercept) Receives the US FDA’s Approval for Serious Retinal Disease

August 21, 2023

$Regeneron Reports EMA Acceptance of MAA for Odronextamab to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma$

Regeneron Reports EMA Acceptance of MAA for Odronextamab to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell...

August 18, 2023

Regeneron’s Veopoz (pozelimab-bbfg) Receives the US FDA’s Approval as First Treatment For Children and Adults With Chaple Disease

Regeneron’s Veopoz (pozelimab-bbfg) Receives the US FDA’s Approval as First Treatment For Children and Adults With Chaple Disease

August 18, 2023

Regeneron Reports Two-Year (PULSAR) Trial Results of Aflibercept for Wet Age-Related Macular Degeneration

Regeneron Reports Two-Year (PULSAR) Trial Results of Aflibercept for Wet Age-Related Macular Degeneration

August 11, 2023

Regeneron to Acquire Decibel Therapeutics to Advance Gene Therapy and Hearing Loss Programs

Regeneron to Acquire Decibel Therapeutics to Advance Gene Therapy and Hearing Loss Programs

August 9, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us